Cost-Effectiveness of Vonoprazan- and Rifabutin-Based vs. Other Regimens as First-Line Treatment of Helicobacter Pylori Infection in the United States.

H. pylori infection eradication with vonoprazan triple therapy would provide the greatest net health and monetary benefit from the perspective of US healthcare payers.